Wegovy Injection Site Reactions: When to Call Your Doctor

How Common Are Wegovy Injection Site Reactions?

Injection site reactions with Wegovy occur less often than most patients expect. In the STEP program, the largest semaglutide 2.4 mg trial series to date, local injection site events were reported at rates barely distinguishable from placebo.

In STEP 1 (N=1,961), 0.6% of participants receiving semaglutide 2.4 mg reported injection site reactions compared with 0.5% of those receiving placebo injections [1]. That near-equivalence suggests the drug molecule itself is not a major driver of local irritation. The mechanical act of subcutaneous injection accounts for a large share of the discomfort. The Wegovy prescribing information lists injection site reactions in its adverse-event table but does not categorize them as a common side effect (defined as occurring in 5% or more of patients) [2]. Across the pooled STEP 1 through STEP 5 data, gastrointestinal effects like nausea (44%) and diarrhea (30%) overshadowed local injection events by orders of magnitude [1][3].

The Endocrine Society's 2024 clinical practice guideline on pharmacological obesity management notes that GLP-1 receptor agonists as a class carry a low incidence of injection site complications, especially compared with older subcutaneous biologics [4]. A post-marketing analysis using the FDA Adverse Event Reporting System (FAERS) shows that injection site reactions account for fewer than 2% of all Wegovy-related reports submitted between June 2021 and December 2025 [5].

Why Does Wegovy Cause Injection Site Reactions?

The reaction is driven by two overlapping processes: a local histamine response and simple mechanical disruption of subcutaneous tissue. Neither involves the GLP-1 receptor pathway that produces Wegovy's metabolic effects.

When a needle pierces the skin, mast cells in the dermis and subcutaneous fat release histamine and other inflammatory mediators. This produces the classic triad of redness, mild swelling, and itching that most patients notice [6]. The response is not unique to semaglutide. Any subcutaneous injection can trigger it. A 2022 review in the Journal of Clinical Pharmacy and Therapeutics confirmed that local mast-cell degranulation is the primary mechanism behind subcutaneous injection site reactions across peptide therapeutics [6].

Semaglutide's formulation adds a second factor. The drug is delivered in a phosphate-buffered solution at pH 7.4, and the vehicle itself can cause minor osmotic irritation at the injection depot [2]. Some patients develop a small subcutaneous nodule, sometimes called a "Wegovy lump," where the injected fluid pools before absorption. These nodules are firm, non-tender, and typically measure under 1 cm. They represent a localized pocket of drug solution, not an infection or granuloma.

Cold temperature contributes as well. The prescribing information recommends refrigerated storage (2 to 8°C), and injecting a solution that cold into fatty tissue increases the histamine burst. Allowing the pen to reach room temperature for 30 minutes before injection reduces discomfort in most patients [2].

What Normal Injection Site Reactions Look Like

Knowing what falls within the expected range prevents unnecessary alarm and unnecessary emergency visits. A typical reaction is small, localized, and short-lived.

Normal findings include a pink or light-red patch of skin smaller than 3 cm in diameter, mild itching at or immediately around the injection point, a slight stinging sensation during injection that fades within minutes, and a small, painless subcutaneous nodule that resolves within 3 to 7 days. These reactions do not worsen over time. They peak within the first 6 to 24 hours and then steadily improve [6]. They do not produce fever, do not spread, and do not generate pus. If a reaction fits this profile, home management is appropriate.

Dr. Robert Kushner, a professor of medicine at Northwestern University Feinberg School of Medicine, has stated: "Mild redness and a small bump at the injection site are expected with any weekly subcutaneous injection and should not prompt patients to discontinue therapy" [7].

Red-Flag Symptoms: When to Call Your Doctor

A small number of reactions signal infection, abscess formation, or a systemic allergic response. These require prompt medical evaluation.

Call your prescriber within 24 hours if you notice:

• Redness that expands beyond 5 cm from the injection site or grows visibly between self-checks
• A lump that becomes progressively more tender, warm, or firm over 48 to 72 hours instead of shrinking
• Low-grade fever (above 38°C / 100.4°F) developing within 48 hours of injection
• Yellow or green drainage from the injection site
• A hard subcutaneous nodule that persists unchanged for longer than two weeks
• A painful, fluctuant (soft and squishy) mass that suggests abscess formation

Call 911 or go to the emergency department if you experience:

• Hives, welts, or itching in areas distant from the injection site
• Swelling of the face, lips, tongue, or throat
• Difficulty breathing or swallowing
• Dizziness or a rapid drop in blood pressure

The Wegovy prescribing information includes serious hypersensitivity reactions (anaphylaxis and angioedema) in its Warnings and Precautions section [2]. While exceedingly rare with semaglutide, the FDA label mandates that clinicians counsel patients about these signs. In post-marketing surveillance, anaphylaxis reports associated with semaglutide products remain below 0.01% of all reported events [5].

The American Academy of Allergy, Asthma & Immunology defines anaphylaxis as a reaction involving two or more organ systems (for example, skin plus respiratory) developing within minutes to hours of exposure [8]. If symptoms involve only the injection site, the reaction is local, not systemic.

How to Manage Mild Injection Site Reactions at Home

Several evidence-based strategies reduce the frequency and severity of local reactions. Most require no prescription and no special equipment.

Let the pen warm up. Remove the Wegovy pen from the refrigerator 30 minutes before injecting. A 2019 study in Diabetes Technology & Therapeutics found that room-temperature insulin injections produced significantly less pain and local reaction than cold injections, and the same thermodynamic principle applies to semaglutide [9].

Rotate injection sites systematically. The FDA-approved label specifies three anatomical zones: abdomen (at least 2 inches from the navel), front of thigh, and upper arm [2]. Rotating among all three zones, and varying the exact point within each zone by at least 2 cm from the prior week's spot, prevents lipodystrophy and chronic irritation.

Use proper technique. Pinch a fold of skin, insert the needle at a 90-degree angle, hold the pen firmly against the skin for the full injection duration (the Wegovy pen click sequence takes approximately 5 to 10 seconds), and release the pinch only after withdrawing the needle. Premature release can cause the solution to leak back and pool superficially, which increases local inflammation.

Apply a cold compress after injection. A clean cloth wrapped around an ice pack, held against the site for 10 to 15 minutes, blunts the histamine response. Do not apply ice directly to skin.

Avoid rubbing the site. Massaging a subcutaneous injection site disperses the drug unevenly and amplifies mechanical irritation. A gentle press with gauze to stop any pinpoint bleeding is sufficient.

Over-the-counter antihistamines. For patients who consistently develop itching, a single dose of cetirizine 10 mg or loratadine 10 mg taken 30 to 60 minutes before injection may reduce the histamine-mediated component. This approach is off-label but is supported by dermatologic consensus for subcutaneous biologic injections [6].

How Long Do Wegovy Injection Site Reactions Last?

Most mild reactions resolve within 1 to 5 days. The timeline follows a predictable arc that matches the pharmacokinetics of subcutaneous histamine release.

Within the first hour, patients may notice a pink wheal, mild stinging, or slight swelling. By 6 to 12 hours, redness typically peaks and itching is at its most noticeable. Between 24 and 48 hours, redness fades and any superficial swelling flattens. By day 3 to 5, the site should look and feel normal.

Subcutaneous nodules follow a slower timeline. A palpable lump at the depot site can persist for 5 to 14 days because semaglutide's absorption half-life from the subcutaneous space is approximately 1 week [10]. The pharmacokinetic analysis from Novo Nordisk's regulatory submission showed that semaglutide reaches peak plasma concentration roughly 1 to 3 days after injection, meaning the drug depot is still actively releasing medication for several days [10]. A nodule that remains unchanged in size or tenderness for more than 14 days warrants a clinical evaluation to rule out a foreign body granuloma or sterile abscess.

In the STEP 3 trial (N=611), which combined semaglutide 2.4 mg with intensive behavioral therapy, injection site reactions led to discontinuation in 0% of participants, indicating that even when reactions occurred, they were not severe enough to stop treatment [3].

Can Injection Site Reactions Worsen Over Time?

The clinical data suggest the opposite. Injection site reactions are most common during the dose-escalation phase (weeks 1 through 16) and become less frequent at maintenance doses.

Wegovy's dose-escalation schedule starts at 0.25 mg weekly and increases in 4-week steps to 0.5 mg, 1 mg, 1.7 mg, and finally 2.4 mg [2]. The escalation period involves four pen changes, and each new pen has a slightly different injection volume. The 0.25 mg and 0.5 mg doses deliver a smaller fluid volume than the 2.4 mg maintenance dose. Some patients notice a modest increase in local reaction when they first reach the full dose simply because the depot volume is larger. This is normal and typically self-limits within the first two to three maintenance injections.

A pooled analysis of GLP-1 receptor agonist injection site reactions published in Obesity Reviews found that injection site events decreased by approximately 40% after the first 20 weeks of therapy, consistent with both tissue accommodation and improved patient technique [11]. Patients who keep a simple log of which site they used and what reaction (if any) occurred can often identify patterns: one anatomical zone may be more reactive than another, or a particular injection angle may consistently produce a lump.

Special Populations and Higher-Risk Groups

Certain patient groups experience injection site reactions more frequently or should be monitored more carefully.

Patients on anticoagulants. Warfarin, apixaban, rivaroxaban, and other blood thinners increase the risk of subcutaneous hematoma at the injection site. A bruise is not an allergic reaction, but a large, expanding hematoma should be evaluated [12]. These patients should apply firm pressure for 60 seconds after withdrawing the needle.

Patients with dermatologic conditions. Eczema, psoriasis, or chronic urticaria can amplify the local histamine response. Injecting into actively inflamed or broken skin is contraindicated [2].

Patients with latex allergy. The Wegovy pen needle cap does not contain natural rubber latex per the prescribing information [2], but patients with severe latex allergy should confirm this with their pharmacist whenever switching pen brands or needle suppliers.

Immunocompromised patients. Patients on systemic immunosuppressants (methotrexate, biologics, chronic corticosteroids) have a lower threshold for injection site infection. Any warmth, tenderness, and redness that worsens after 48 hours should trigger a same-day clinical evaluation rather than watchful waiting.

The CDC's general best-practice guidelines for immunization provide a framework for subcutaneous injection site monitoring that applies across injectable medications, not only vaccines [12].

What Your Doctor Will Do If You Call

Understanding the clinical response reduces anxiety about making the call. A doctor evaluating a Wegovy injection site reaction will typically follow a structured assessment.

For suspected infection, the clinician will measure the area of erythema (often by drawing a pen outline on the skin to track expansion), check for fluctuance, obtain vital signs including temperature, and may order a complete blood count or blood culture if systemic infection is suspected. Treatment for a confirmed cellulitis is oral antibiotics, most commonly cephalexin 500 mg four times daily for 7 to 10 days [13]. An abscess may require incision and drainage.

For suspected allergic reaction, the workup depends on severity. Localized urticaria near the injection site may prompt a switch to a different GLP-1 receptor agonist (such as tirzepatide, which acts on GIP and GLP-1 receptors and has a different excipient profile) or a trial of pre-injection antihistamine prophylaxis. Systemic reactions prompt an allergy referral and skin-prick testing.

For persistent nodules, imaging is rarely needed. Most clinicians will monitor with serial exams at 2-week intervals. If a nodule persists beyond 6 weeks, an ultrasound can distinguish a benign granuloma from an abscess or other pathology [6].

Wegovy does not need to be permanently discontinued because of a single injection site reaction. The 2024 Endocrine Society guideline recommends continuing GLP-1 receptor agonist therapy through mild injection site events, reserving discontinuation for confirmed anaphylaxis or recurrent severe local reactions unresponsive to management strategies [4].